Overview

Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL)

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Miltefosine efficacy will be >85%
Phase:
Phase 2
Details
Lead Sponsor:
AB Foundation
Collaborator:
World Health Organization
Treatments:
Miltefosine